Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | PDE6D | O43924 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.43 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14921162 | 0.88 | ESR1 (0.47) | ESR1PDE6DALDH1A1POLBHTT | |
| SCHEMBL5662079 | 0.84 | ESR1 (0.69) | ESR1PDE6DPLAAALPGCYP3A4 | |
| SCHEMBL16212158 | 0.84 | ESR1 (0.56) | ESR1PDE6DALDH1A1POLBHTT | |
| SCHEMBL13587978 | 0.84 | ESR1 (0.56) | ESR1PDE6DALDH1A1POLBHTT | |
| SCHEMBL5707890 | 0.80 | ESR1 (0.67) | ESR1PDE6DALDH1A1PLAAALPG | |
| SCHEMBL7095574 | 0.77 | ESR1 (0.68) | ESR1PDE6DALDH1A1POLBPLAA | |
| SCHEMBL27452733 | 0.77 | ESR1 (0.63) | ESR1PDE6DPLAAALPGCYP3A4 | |
| SCHEMBL13587983 | 0.77 | ESR1 (0.63) | ESR1PDE6DPLAAALPGCYP3A4 | |
| SCHEMBL5657679 | 0.75 | ESR1 (0.61) | ESR1PDE6DPLAAALPGCYP3A4 | |
| SCHEMBL9444420 | 0.74 | ESR1 (0.64) | ESR1PDE6DALDH1A1POLBPLAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773378-B1 | PRODRUGS OF NON-STEROID ANTI-INFLAMMATORY AGENTS (NSAIDS) | SELCH LARSEN CLAUS (DK) | 2016-08-10 | — | — | EP | claimed |
| US-9937262-B2 | Prodrugs of naproxen and diclofenac | LARSEN, CLAUS SELCH (DK) | 2018-04-10 | — | — | US | disclosed |
| US-9809557-B2 | Prodrugs of non-steroid anti-inflammatory agents (NSAIDS) | SELCH LARSEN CLAUS (DK) | 2017-11-07 | — | — | US | disclosed |
| US-9809557-B2 | Prodrugs of non-steroid anti-inflammatory agents (NSAIDS) | SELCH LARSEN CLAUS (DK) | 2017-11-07 | — | — | US | disclosed |
| US-9809557-B2 | Prodrugs of non-steroid anti-inflammatory agents (NSAIDS) | SELCH LARSEN CLAUS (DK) | 2017-11-07 | — | — | US | disclosed |
| EP-2991682-B1 | PRODRUGS OF NAPROXEN AND DICLOFENAC | SELCH LARSEN CLAUS (DK) | 2017-04-19 | — | — | EP | disclosed |
| EP-2773378-B1 | PRODRUGS OF NON-STEROID ANTI-INFLAMMATORY AGENTS (NSAIDS) | SELCH LARSEN CLAUS (DK) | 2016-08-10 | — | — | EP | disclosed |
| US-20160074523-A1 | PRODRUGS OF NAPROXEN AND DICLOFENAC | LARSEN, CLAUS SELCH (DK) | 2016-03-17 | — | — | US | disclosed |
| EP-2991682-A1 | PRODRUGS OF NAPROXEN AND DICLOFENAC | Larsen, Claus Selch (DK) | 2016-03-09 | — | — | EP | disclosed |
| WO-2014177479-A1 | PRODRUGS OF NAPROXEN AND DICLOFENAC | SELCH LARSEN CLAUS (DK) | 2014-11-06 | — | — | WO | disclosed |
| US-20140315960-A1 | PRODRUGS OF NON-STEROID ANTI-INFLAMMATORY AGENTS (NSAIDS) | SELCH LARSEN CLAUS (DK) | 2014-10-23 | — | — | US | disclosed |
| US-20140315960-A1 | PRODRUGS OF NON-STEROID ANTI-INFLAMMATORY AGENTS (NSAIDS) | SELCH LARSEN CLAUS (DK) | 2014-10-23 | — | — | US | disclosed |
| US-20140315960-A1 | PRODRUGS OF NON-STEROID ANTI-INFLAMMATORY AGENTS (NSAIDS) | SELCH LARSEN CLAUS (DK) | 2014-10-23 | — | — | US | disclosed |
| EP-2773378-A1 | PRODRUGS OF NON- STEROID ANTI - INFLAMMATORY AGENTS (NSAIDS) | Larsen, Claus Selch (DK) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013064153-A1 | PRODRUGS OF NON- STEROID ANTI - INFLAMMATORY AGENTS (NSAIDS) | SELCH LARSEN CLAUS (DK) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315960-A1 | PRODRUGS OF NON-STEROID ANTI-INFLAMMATORY AGENTS (NSAIDS) | MMP1, MIF, CYP21A2 | ESR1 1365/4885PDE6D 1521/4885ALDH1A1 406/4885 |
| US-20160074523-A1 | PRODRUGS OF NAPROXEN AND DICLOFENAC | CYP2D6, CYP2U1, PTGER1 | ESR1 2088/4885PDE6D 545/4885ALDH1A1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.